The clinical implications of the genetics of renal cell carcinoma.

[1]  M. Merino,et al.  The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome , 2007, The American journal of surgical pathology.

[2]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[3]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[4]  W. Linehan,et al.  HIF and fumarate hydratase in renal cancer , 2007, British Journal of Cancer.

[5]  E. Maher,et al.  Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.

[6]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[7]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Linehan,et al.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. , 2005, Journal of the National Cancer Institute.

[9]  Peter L Choyke,et al.  Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. , 2005, American journal of human genetics.

[10]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[11]  Peter L Choyke,et al.  The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. , 2005, The Journal of urology.

[12]  Joan Borràs,et al.  Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. , 2004, The Journal of urology.

[13]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[14]  W Marston Linehan,et al.  Focus on kidney cancer. , 2004, Cancer cell.

[15]  J. Brugarolas,et al.  Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. , 2004, Cancer cell.

[16]  P. Albert,et al.  Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location , 2004, Human mutation.

[17]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[19]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[20]  G. V. Vande Woude,et al.  HGF/SF‐met signaling in the control of branching morphogenesis and invasion , 2003, Journal of cellular biochemistry.

[21]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[22]  W. Linehan.  Editorial: Kidney cancer--a unique opportunity for the development of disease specific therapy. , 2002, The Journal of urology.

[23]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[24]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[25]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  N. Masumori,et al.  Recurrence of renal cell carcinoma more than 5 years after nephrectomy , 2002, International journal of urology : official journal of the Japanese Urological Association.

[27]  W. Linehan,et al.  Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. , 2001, American journal of human genetics.

[28]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[30]  P L Choyke,et al.  Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. , 1999, The Journal of urology.

[31]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[32]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[33]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[34]  P. Choyke,et al.  Imaging features of hereditary papillary renal cancers. , 1997, Journal of computer assisted tomography.

[35]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[36]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Zbar,et al.  Renal cysts, renal cancer and von Hippel-Lindau disease. , 1997, Kidney international.

[38]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Linehan,et al.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.

[40]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[41]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[42]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[43]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[44]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[45]  P. Choyke,et al.  Hereditary papillary renal cell carcinoma. , 1994, The Journal of urology.

[46]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[47]  G. Kovacs,et al.  Molecular cytogenetics of renal cell tumors. , 1993, Advances in cancer research.

[48]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[49]  G. Kovacs,et al.  Cytogenetics of renal cell carcinomas associated with von hippel‐Lindau disease , 1991, Genes, chromosomes & cancer.

[50]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[51]  Y. Nakamura,et al.  Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.

[52]  H. Brauch,et al.  Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.

[53]  R. Harris,et al.  Genetics of Human Cancer , 1977, British Journal of Cancer.